β-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection.

PubWeight™: 0.77‹?›

🔗 View Article (PMC 4520544)

Published in Gene Ther on March 19, 2015

Authors

M M El Khatib1, T Sakuma1, J M Tonne1, M S Mohamed1, S J Holditch1, B Lu1, Y C Kudva2, Y Ikeda1

Author Affiliations

1: Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA.
2: Division of Endocrinology, Mayo Clinic College of Medicine, Rochester, MN, USA.

Articles citing this

PD-L1 Deficiency within Islets Reduces Allograft Survival in Mice. PLoS One (2016) 0.75

Articles cited by this

International trial of the Edmonton protocol for islet transplantation. N Engl J Med (2006) 13.43

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84

Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med (1991) 8.78

Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med (2003) 8.47

Five-year follow-up after clinical islet transplantation. Diabetes (2005) 7.86

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20

Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature (2010) 5.16

Recovery from diabetes in mice by beta cell regeneration. J Clin Invest (2007) 4.32

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes (2005) 4.19

Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev (2011) 4.15

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011) 4.15

Type 1 diabetes. Lancet (2006) 3.61

Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care (2012) 3.20

Islet transplantation as a treatment for diabetes - a work in progress. N Engl J Med (2004) 2.68

Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care (2003) 1.86

Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant (2008) 1.68

A method for murine islet isolation and subcapsular kidney transplantation. J Vis Exp (2011) 1.49

M2 macrophages promote beta-cell proliferation by up-regulation of SMAD7. Proc Natl Acad Sci U S A (2014) 1.35

Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes (2013) 1.30

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care (2013) 1.21

The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time. Ann Med (2010) 1.01

Death and dysfunction of transplanted β-cells: lessons learned from type 2 diabetes? Diabetes (2014) 0.96

Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol (2002) 0.96

Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced β-cell damage and pancreatic Glp-1 gene therapy. Dis Model Mech (2013) 0.91

The pros and cons of immunomodulatory IL-10 gene therapy with recombinant AAV in a Cftr-/- -dependent allergy mouse model. Gene Ther (2008) 0.88

Concise review: pluripotent stem cell-based regenerative applications for failing β-cell function. Stem Cells Transl Med (2014) 0.88

Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. Transplantation (2011) 0.87

Beta cell regeneration after single-round immunological destruction in a mouse model. Diabetologia (2014) 0.78